Loading…
Atea Pharmaceuticals, Inc. is projected to rise to $5.31 by 2027, a +13% move from its current price of $4.70. AVIR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $4.59 | $4.70 | $4.81 | +0.01% |
| Aug 4 | $4.55 | $4.70 | $4.86 | +0.02% |
| Aug 5 | $4.52 | $4.70 | $4.89 | +0.03% |
| Aug 6 | $4.49 | $4.70 | $4.92 | +0.03% |
| Aug 7 | $4.47 | $4.70 | $4.95 | +0.04% |
| Aug 8 | $4.45 | $4.70 | $4.97 | +0.05% |
| Aug 9 | $4.43 | $4.70 | $5.00 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.43 | $4.70 | $5.00 | +0.06% |
| Week 2 | $4.32 | $4.71 | $5.13 | +0.12% |
| Week 3 | $4.24 | $4.71 | $5.23 | +0.18% |
| Week 4 | $4.17 | $4.71 | $5.32 | +0.24% |
| Week 5 | $4.12 | $4.71 | $5.40 | +0.30% |
| Week 6 | $4.07 | $4.72 | $5.47 | +0.36% |
| Week 7 | $4.02 | $4.72 | $5.54 | +0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
The company is also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. It offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir.
Atea was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR trades in the healthcare sector. The current price is $4.51 and the market capitalization is $360.92M, with a rank of 3184.
The stock’s near-term technical picture shows the 50-day simple moving average at $4.54 and the 200-day simple moving average at $4.31, with the price trading in a zone close to these averages.
Forecasts indicate a multi-year uptrend, with the average price rising from $4.51 in 2026 to $28.96 by 2050 and the ROI expanding from 0% in 2026 to 542.1% in 2050. The sentiment remains NEUTRAL through 2028, turning BULLISH from 2029 onward.
Over the 30-day window, the range is projected from $3.93 to $5.17.
A major floor 14.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 27.0% above — clearing it would confirm fresh momentum.
Key AVIR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVIR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.68 | Buy | $4.70 | Buy |
| MA 10 | $4.73 | Sell | $4.72 | Sell |
| MA 20 | $4.78 | Sell | $4.72 | Sell |
| MA 50 | $4.58 | Buy | $4.73 | Sell |
| MA 100 | $5.05 | Sell | $4.71 | Sell |
| MA 200 | $4.35 | Buy | $4.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.50 | Neutral |
| Stoch RSI (14) | 50.51 | Neutral |
| CCI (20) | -65.11 | Neutral |
| Williams %R (14) | -47.22 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -3.29 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 52.78 | Neutral |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 46.17 | Neutral |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 4.63 | Buy |
| ADX (14) | 9.33 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50. The stock currently trades near the SMA50 of $4.54 and above the SMA200 of $4.31.
Key near-term levels place support at $4.26 and resistance at $4.99, defining a narrow range for near-term moves.
The thirty-day price range is projected from $3.93 to $5.17, illustrating limited near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.40 | $4.70 | $6.01 | 0% | Neutral | |
| $4.30 | $5.31 | $6.90 | +13% | Neutral | |
| $4.49 | $5.68 | $7.61 | +21% | Bullish | |
| $4.95 | $6.38 | $8.78 | +36% | Bullish | |
| $5.01 | $6.57 | $9.24 | +40% | Bullish | |
| $5.94 | $7.90 | $11.31 | +68% | Bullish | |
| $7.34 | $9.90 | $14.41 | +111% | Bullish | |
| $7.36 | $10.07 | $14.88 | +114% | Bullish | |
| $7.80 | $10.80 | $16.18 | +130% | Bullish | |
| $8.36 | $11.71 | $17.78 | +149% | Bullish | |
| $12.76 | $18.87 | $30.24 | +302% | Bullish | |
| $19.88 | $32.17 | $55.84 | +584% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.40 | $4.70 | $5.78 | +0.00% |
| September 2026 | $4.11 | $4.83 | $5.83 | +2.84% |
| October 2026 | $4.00 | $4.74 | $5.77 | -1.99% |
| November 2026 | $4.03 | $4.79 | $5.88 | +1.17% |
| December 2026 | $4.07 | $4.87 | $6.01 | +1.55% |
Click any year to see its month-by-month AVIR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AVIR to range from $3.40 to $6.01 through 2026. The $4.70 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The AVIR price prediction for 2027 points to an average of $5.31 (low $4.30, high $6.90) — a potential gain of +13% on today's $4.70. Price action looks broadly range-bound.
In 2028, AVIR is projected to trade between $4.49 and $7.61, averaging $5.68 — a potential gain of +21% from today's $4.70. That is up +7% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Atea Pharmaceuticals, Inc.'s 2029 outlook centres on $6.38, within a $4.95 to $8.78 range. That is up +12% on the projected 2028 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2030, AVIR could reach as high as $9.24, with a base case around $6.57 and support toward $5.01 — roughly +40% from $4.70. Buyers look set to stay in control over this stretch.
Expect AVIR to range from $5.94 to $11.31 through 2031. The $7.90 average target implies a +68% move from current prices. That is up +20% on the projected 2030 average. Momentum favours further upside here.
The AVIR price prediction for 2032 points to an average of $9.90 (low $7.34, high $14.41) — a potential gain of +111% on today's $4.70. Buyers look set to stay in control over this stretch.
In 2033, AVIR is projected to trade between $7.36 and $14.88, averaging $10.07 — a potential gain of +114% from today's $4.70. That is up +2% on the projected 2032 average. Momentum favours further upside here.
Atea Pharmaceuticals, Inc.'s 2034 outlook centres on $10.80, within a $7.80 to $16.18 range. That is up +7% on the projected 2033 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, AVIR could reach as high as $17.78, with a base case around $11.71 and support toward $8.36 — roughly +149% from $4.70. Momentum favours further upside here.
Expect AVIR to range from $12.76 to $30.24 through 2040. The $18.87 average target implies a +302% move from current prices. That is up +61% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The AVIR price prediction for 2050 points to an average of $32.17 (low $19.88, high $55.84) — a potential gain of +584% on today's $4.70. Momentum favours further upside here.
Investing $1,000 in AVIR today (≈ 212.765957 AVIR) could be worth
$6,844.11
+$5,844.11 (+584%) by 2050 · US Dollar
Based on the average projected AVIR price of $32.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVIRwould be worth at today's price.
$1,000 invested in AVIR on Jul 31, 2025 (≈ 274.725267 AVIR) would be worth
$1,291.21
+$291.21 (+29.1%) today · 1.29× · US Dollar
Based on a AVIR entry price of $3.64 vs. today's $4.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.73 | $993.66 | -0.6% |
| 1 month ago | $4.78 | $983.26 | -1.7% |
| 3 months ago | $5.58 | $842.29 | -15.8% |
| 6 months ago | $4.07 | $1,154.79 | +15.5% |
| 1 year ago | $3.64 | $1,291.21 | +29.1% |
| All time (5.0y) ago | $27.84 | $168.82 | -83.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVIR forecast.
Our base-case forecast reaches $9.40 around 2032.
Implied market cap at $9.40: $752.25M
The multi-year forecast shows a gradual upward trajectory with a shift to bullish sentiment beginning in 2029. The 2026 forecast lists an avg price of $4.51 with ROI of 0% and NEUTRAL sentiment, followed by 2027 with avg $5.07 and ROI 12.4. The 2028 forecast shows avg $5.41 and ROI 19.9, keeping sentiment NEUTRAL, and 2029 signals a bullish turn with avg $6.01 and ROI 33.3.
By 2030, the avg price is $6.18 with ROI 37 and sentiment BULLISH. The next years show continued gains: 2031 avg $7.39 (ROI 64), 2032 avg $9.15 (ROI 103), 2033 avg $9.30 (ROI 106.1), 2034 avg $10.00 (ROI 121.6), and 2035 avg $10.79 (ROI 139.2), all with bullish sentiment.
Looking further out, 2040 projects an avg price of $17.18 (min $11.94, max $26.81) with ROI 280.9 and bullish sentiment. By 2050 the forecast calls for an avg price of $28.96 (min $18.59, max $48.69) with ROI 542.1 and bullish sentiment. These are estimates, not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast lists an avg price of $6.18 with ROI 37 and a bullish sentiment.
Forecasts show a long-term bullish path beginning around 2029, with the average price rising to $28.96 by 2050 and ROI up to 542.1%. These are estimates, not guarantees.
Yes. The 2032 forecast shows a max of $13.07 and an avg of $9.15, so a $10 level is within the projected range.
The 2040 forecast has an avg price of $17.18, with a min of $11.94 and a max of $26.81, and ROI of 280.9 with bullish sentiment.
For 2050, the forecast shows an avg price of $28.96, with a min of $18.59, a max of $48.69, and ROI of 542.1, with bullish sentiment.
Atea Pharmaceuticals, Inc. Community Discussion
0Share your Atea Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.